Last Updated: May 10, 2026

Claims for Patent: 12,558,349

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,558,349

Title:	Methods of treating infections in overweight and obese patients using antibiotics
Abstract:	The present disclosure relates generally to methods of treating infections in overweight or obese patients using antibiotics.
Inventor(s):	Erin M. Duffy
Assignee:	Melinta Subsidiary Corp
Application Number:	US18/324,754
Patent Claims:	1. A method of treating an Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in an overweight or obese patient in need thereof, the method comprising intravenously (IV) administering to the patient a composition comprising 433 mg of delafloxacin meglumine salt which corresponds to 300 mg of delafloxacin, twice a day. 2. The method of claim 1, wherein the overweight or obese patient has a body mass index greater than 25. 3. The method of claim 2, wherein the overweight or obese patient has a body mass index greater than or equal to 30. 4. The method of claim 3, wherein the overweight or obese patient has a body mass index greater than or equal to 35. 5. The method of claim 4, wherein the overweight or obese patient has a body mass index greater than or equal to 40. 6. The method of claim 1, wherein the composition further comprises beta-cyclodextrin sulfobutyl ether. 7. The method of claim 6, wherein the amount of beta-cyclodextrin sulfobutyl ether is 2400 mg. 8. The method of claim 1, wherein the composition further comprises disodium EDTA. 9. The method of claim 8, wherein the amount of disodium EDTA is 1.32 mg. 10. The method of claim 1, wherein the composition further comprises meglumine. 11. The method of claim 10, wherein the amount of meglumine is 58.56 mg. 12. A method of treating an Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in an overweight or obese patient in need thereof, the method comprising intravenously (IV) administering to the patient twice a day a composition comprising 433 mg of delafloxacin meglumine salt which corresponds to 300 mg of delafloxacin, wherein the composition comprises: (1) 25 mg/mL of delafloxacin meglumine, calculated as free acid; (2) 4.88 mg/mL of meglumine; and (3) 200 mg/mL of beta-cyclodextrin sulfobutyl ether.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.